8-K: Immuneering's Atebimetinib Boosts Pancreatic Cancer Survival

Immuneering Corporation announced updated interim Phase 2a clinical trial data for atebimetinib in first-line pancreatic cancer, demonstrating significantly improved overall survival compared to standard of care.

Summary

• Immuneering Corporation reported updated interim data from its Phase 2a clinical trial of atebimetinib (a MEK inhibitor) combined with modified Gemcitabine/nab-Paclitaxel (mGnP) for first-line pancreatic cancer patients.
• As of December 15, 2025, the 320 mg once-daily dose in 34 patients showed 64% overall survival (OS) at 12 months, significantly higher than the 35% OS reported for the standard of care.
• The median overall survival for this patient population had not yet been reached, with a median follow-up time of 13.4 months.
• Median progression-free survival (PFS) was 8.5 months.
• Six-month OS was 94% (vs. 67% for standard of care) and nine-month OS was 83% (vs. ~47% for standard of care, extrapolated).
• The combination therapy was generally well tolerated, with no Grade 5 treatment-emergent adverse events (TEAEs) and no new safety signals identified.
• Common Grade ≥3 TEAEs (≥10% of patients) included Anemia (18%) and Neutropenia (18%).

Sentiment

Score: 9

Explanation: The filing reports highly positive interim clinical trial data for atebimetinib in first-line pancreatic cancer, showing a near doubling of 12-month overall survival compared to standard of care, with a generally well-tolerated safety profile. This represents a significant potential advancement in a disease with high unmet need.

Positives

• 64% overall survival (OS) at 12 months in the 320 mg ITT Population (N=34), significantly exceeding the 35% OS reported for standard of care.
• Median OS had not been reached as of the cutoff date (December 15, 2025), indicating prolonged survival with a median follow-up time of 13.4 months.
• Median progression-free survival (PFS) was 8.5 months.
• High 6-month OS of 94% (vs. 67% standard of care) and 9-month OS of 83% (vs. ~47% standard of care, extrapolated).
• Atebimetinib in combination with mGnP continued to be generally well tolerated.
• No Grade 5 treatment-emergent adverse events (TEAEs) were observed.
• No new safety signals were identified.

Negatives

• Grade ≥3 treatment-emergent adverse events (TEAEs) observed in 10% or greater of patients included Anemia (18%) and Neutropenia (18%).
• The trial does not include a head-to-head comparison against any other agents, requiring caution when comparing data across trials.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
• Factors that could cause actual results to differ include those discussed under "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• Caution should be exercised when comparing data across trials, as the Phase 1/2a clinical trial does not include a head-to-head comparison against other agents.

Future Outlook

Immuneering expects to present further updated circulating tumor DNA data on acquired alterations from cancer patients treated with atebimetinib at a major scientific meeting in the second quarter of 2026. The company also anticipates announcing further updated survival data from over 50 first-line pancreatic cancer patients in the first half of 2026. A pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP for first-line pancreatic cancer is expected to dose its first patient in mid-2026, and a clinical trial of atebimetinib with Libtayo in non-small cell lung cancer patients is planned to dose its first patient in the second half of 2026.

Management Comments

• "The Company announced that, as of a cutoff date of December 15, 2025, 64% overall survival (OS) at 12 months (with median follow-up time of 13.4 months) was observed in the initial intent-to-treat population of 34 patients dosed at the 320 mg once-daily dose level of atebimetinib in combination with mGnP."
• "The Company also announced that, as of the Cutoff Date, atebimetinib in combination with mGnP continued to be generally well tolerated."
• "No Grade 5 TEAEs were observed in this patient population and no new safety signals were identified."

Industry Context

Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, with a very poor prognosis and high unmet medical need. Standard of care treatments often provide limited survival benefits. The reported data for atebimetinib, a MEK inhibitor, in combination with mGnP, showing a significant improvement in overall survival compared to historical standard of care data, suggests a potentially meaningful advancement in the treatment landscape for first-line pancreatic cancer. MEK inhibitors are a class of targeted therapies that block a specific pathway involved in cancer cell growth.

Comparison to Industry Standards

• The 12-month overall survival (OS) of 64% for atebimetinib plus mGnP significantly surpasses the 35% OS reported from the publicly available third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel (standard of care).
• The 6-month OS of 94% for atebimetinib plus mGnP compares favorably to the 67% OS reported from the MPACT pivotal trial data for standard of care.
• The 9-month OS of 83% for atebimetinib plus mGnP is substantially higher than the ~47% OS estimated by the Company based on extrapolated and reconstructed MPACT pivotal trial data for standard of care.
• While direct head-to-head comparisons are not available, the observed survival rates for atebimetinib in this Phase 2a trial appear to represent a substantial improvement over established benchmarks for first-line pancreatic cancer.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potentially increasing company valuation and future revenue prospects.
• Patients: Significant potential benefit for first-line pancreatic cancer patients, offering a new treatment option with substantially improved survival rates.
• Medical Community: Provides promising new data for a challenging cancer, potentially influencing future treatment guidelines and research.

Next Steps

• Present further updated circulating tumor DNA data on acquired alterations from cancer patients treated with atebimetinib at a major scientific meeting in the second quarter of 2026.
• Announce further updated survival data from over 50 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in the first half of 2026.
• Dose the first patient in a pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients in mid-2026.
• Dose the first patient in a clinical trial of atebimetinib in combination with Libtayo in non-small cell lung cancer patients in the second half of 2026.

Key Dates

Recommendation

The interim Phase 2a data for atebimetinib in first-line pancreatic cancer demonstrates a highly significant improvement in overall survival (64% at 12 months vs. 35% for standard of care) in a disease with extremely poor prognosis and high unmet medical need. The median OS not being reached further underscores the potential for extended patient benefit. Coupled with a generally well-tolerated safety profile and clear progression to a pivotal Phase 3 trial, these results de-risk the asset considerably and position Immuneering for substantial future growth. This data suggests a potential best-in-class profile for atebimetinib in this indication, making it a compelling investment opportunity.

Keywords

Immuneering Corporation, atebimetinib, pancreatic cancer, MEK inhibitor, clinical trial, overall survival, progression-free survival, oncology, drug development, biotechnology